196 related articles for article (PubMed ID: 34155608)
1. Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.
Sharma S; Sharma T; Prasad S; Gopalakrishnan M; Chaturvedi A
Ophthalmol Ther; 2021 Sep; 10(3):431-443. PubMed ID: 34155608
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.
Sharma S; Gupta V; Maiti A; Natesh S; Saxena S; Dave V; Parmar V; Sampangi R; Murthy H; Dharwadkar S; Yadav NK; Joshi S; Mayor R; Ratra D; Basu S; Goel N; Chaturvedi A; Patel R; Jose V
Int J Retina Vitreous; 2021 Mar; 7(1):24. PubMed ID: 33762008
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab.
Verma L; Thulasidas M; Purohit A; Gupta A; Narula R; Talwar D
Indian J Ophthalmol; 2021 Feb; 69(2):347-351. PubMed ID: 33463589
[TBL] [Abstract][Full Text] [Related]
4. Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study.
Sharma S; Khan MA; Chaturvedi A;
Ophthalmologica; 2019; 241(1):24-31. PubMed ID: 29945143
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World's First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration.
Sharma S; Khan M; Chaturvedi A;
Ophthalmol Ther; 2020 Mar; 9(1):103-114. PubMed ID: 31883056
[TBL] [Abstract][Full Text] [Related]
6. A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion.
Sharma S; ; Khan M; Chaturvedi A
Ophthalmol Ther; 2020 Sep; 9(3):625-639. PubMed ID: 32617913
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?
Chatzimichail E; Pfau K; Gatzioufas Z; Panos GD
Drug Des Devel Ther; 2024; 18():365-374. PubMed ID: 38347957
[TBL] [Abstract][Full Text] [Related]
8. Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence.
Soman M; Nair I; Sheth JU; Nair U
Ophthalmol Ther; 2022 Jun; 11(3):1175-1186. PubMed ID: 35412266
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study.
Chakraborty D; Sengupta S; Mondal S; Boral S; Das A; Sinha TK; Bhattacharya R; Maitra R
Ophthalmol Ther; 2022 Apr; 11(2):629-638. PubMed ID: 35075621
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study).
Sharma A; Kumar N; Parachuri N; Bandello F; Kuppermann BD; Loewenstein A
Eye (Lond); 2022 May; 36(5):1106-1107. PubMed ID: 34158653
[No Abstract] [Full Text] [Related]
12. Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation.
Ratra D; Roy K; Giridhar S; Madaan S;
Ophthalmol Ther; 2022 Feb; 11(1):135-149. PubMed ID: 34738211
[TBL] [Abstract][Full Text] [Related]
13. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema.
Zhang Y; Yao Z; Kaila N; Kuebler P; Visich J; Maia M; Tuomi L; Ehrlich JS; Rubio RG; Campochiaro PA
Ophthalmology; 2014 Nov; 121(11):2237-46. PubMed ID: 25001159
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
Ou WC; Brown DM; Payne JF; Wykoff CC
Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
[TBL] [Abstract][Full Text] [Related]
16. Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab.
Narayanan R; Kelkar A; Abbas Z; Goel N; Soman M; Naik N; Sudhalkar A; Walinjkar J; Shah U; Maksane N
BMC Ophthalmol; 2021 Jan; 21(1):33. PubMed ID: 33435908
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model.
Cui Z; Zhou W; Chang Q; Zhang T; Wang H; Meng X; Liu Y; Yan H
Front Med (Lausanne); 2021; 8():750132. PubMed ID: 34926500
[No Abstract] [Full Text] [Related]
19. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
